Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

@inproceedings{Heijde2017TofacitinibIP,
  title={Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study},
  author={D{\'e}sir{\'e}e Mfm van der Heijde and Atul A Deodhar and James Cheng-Chung Wei and Edit Drescher and Dona L. Fleishaker and Thijs K Hendrikx and David Li and Sujatha S Menon and Keith S Kanik},
  booktitle={Annals of the rheumatic diseases},
  year={2017}
}
OBJECTIVES To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS